Oral glucocorticosteroid-sparing effect of budesonide administered by Turbuhaler: a double-blind, placebo-controlled study in adults with moderate-to-severe chronic asthma. Pulmicort Turbuhaler Study Group.

OBJECTIVE To determine the ability of budesonide via an inhaler (Pulmicort Turbuhaler; Astra Draco AB) to replace oral glucocorticosteroids (GCSs) in adult subjects with moderate-to-severe asthma. DESIGN Double-blind, randomized, and placebo-controlled study, with parallel groups. SETTING Multicenter study in outpatient setting. PARTICIPANTS Eighty men and 79 women, aged 20 to 69 years, with moderate-to-severe asthma and a mean FEV1 of 58.3% predicted normal. All subjects were receiving oral GCS treatment and 79% of subjects were also receiving inhaled beclomethasone dipropionate (BDP). The mean daily doses of prednisone at baseline, including converted dose of BDP, for the placebo, budesonide 400 microg, and budesonide 800 microg, respectively, were 19.7 mg, 19.5 mg, and 18.7 mg. MEASUREMENTS AND INTERVENTIONS After a 2-week baseline period, subjects entered a 20-week treatment period, during which the oral dose of prednisone was reduced by forced down-titration at 2-weekly intervals. RESULTS Subjects receiving 400 microg or 800 microg bid of budesonide achieved a significantly greater reduction (82.9% and 79.0% respectively) in oral GCS dose compared with placebo-treated subjects (27%; p<0.001). Two thirds of the subjects receiving budesonide were able to achieve sustained oral corticosteroid cessation, compared with 8% in the placebo group. Additionally, both doses of budesonide resulted in significant improvement in results of pulmonary function tests and asthma symptoms scores, and a significant decrease in the use of bronchodilator therapy. The mean plasma cortisol levels before and after adrenocorticotropic hormone stimulation increased most toward the normal range in the budesonide-treated groups compared with placebo-treated subjects. CONCLUSION Budesonide administered via Turbuhaler has a significant oral GCS-sparing capacity with maintained or improved asthma control in adult subjects with moderate-to-severe asthma.

[1]  I. Bernstein,et al.  A placebo-controlled multicenter study of auranofin in the treatment of patients with corticosteroid-dependent asthma. Auranofin Multicenter Drug Trial. , 1996, The Journal of allergy and clinical immunology.

[2]  W. Busse,et al.  Fluticasone propionate reduces oral prednisone use while it improves asthma control and quality of life. , 1995, American journal of respiratory and critical care medicine.

[3]  P. Barnes,et al.  Inhaled glucocorticoids for asthma. , 1995, The New England journal of medicine.

[4]  M. Zureik,et al.  Lung deposition of budesonide from Turbuhaler is twice that from a pressurized metered-dose inhaler P-MDI. , 1994, The European respiratory journal.

[5]  G. Toews,et al.  The role of methotrexate in the management of steroid-dependent asthma. , 1994, Chest.

[6]  E. Flannery,et al.  Methotrexate in the management of severe steroid dependent asthma. , 1993, The New Zealand medical journal.

[7]  M. Gershwin,et al.  Unconventional approaches to drug therapy in severe asthma. , 1993, Allergologia et immunopathologia.

[8]  D. Taylor,et al.  Steroid–sparing agents in the treatment of asthma , 1992, The Medical journal of Australia.

[9]  J. Lötvall,et al.  Effect of dexamethasone and cyclosporin A on allergen-induced airway hyperresponsiveness and inflammatory cell responses in sensitized Brown-Norway rats. , 1992, The American review of respiratory disease.

[10]  E. Gelfand,et al.  Alternative treatments for asthma: assessing the need. , 1992, The Journal of asthma : official journal of the Association for the Care of Asthma.

[11]  P. Barnes.  Asthma. New therapeutic approaches. , 1992, British medical bulletin.

[12]  R. Djukanović,et al.  Mucosal inflammation in asthma. , 1990, The American review of respiratory disease.

[13]  L. Boulet,et al.  Tolerance to reduction of oral steroid dosage in severely asthmatic patients receiving nedocromil sodium. , 1990, Respiratory medicine.

[14]  J. Baskerville,et al.  Bioequivalent doses of budesonide and prednisone in moderate and severe asthma. , 1989, The Journal of allergy and clinical immunology.

[15]  J. Goldin,et al.  Does nedocromil sodium have a steroid sparing effect in adult asthmatic patients requiring maintenance oral corticosteroids? , 1988, Thorax.

[16]  S. Tarlo,et al.  Six-month double-blind, controlled trial of high dose, concentrated beclomethasone dipropionate in the treatment of severe chronic asthma. , 1988, Chest.

[17]  J. Morris,et al.  Fifteen-year interval spirometric evaluation of the Oregon predictive equations. , 1988, Chest.

[18]  B. Weeke,et al.  High-dose inhaled budesonide in treatment of severe steroid-dependent asthma. , 1986, European journal of respiratory diseases.

[19]  I. Bernstein,et al.  Multicenter study of flunisolide aerosol in adult patients with steroid-dependent asthma. , 1980, The Journal of allergy and clinical immunology.

[20]  J. Thijssen,et al.  A quantitative assay of cortisol in human plasma by high performance liquid chromatography using a selective chemically bonded stationary phase. , 1977, Clinica chimica acta; international journal of clinical chemistry.

[21]  N. Lefcoe,et al.  A graded dose assessment of the efficacy of beclomethasone dipropionate aerosol for severe chronic asthma. , 1977, Journal of Allergy and Clinical Immunology.

[22]  I. Kass,et al.  Beclomethasone dipropionate aerosol in the treatment of steroid-dependent asthma. A 12-week double-blind study comparing beclomethasone dipropionate and a vehicle aerosol. , 1976, Chest.

[23]  W. Foulds,et al.  Hydrocortisone in treatment of allergic conjunctivitis, allergic rhinitis, and bronchial asthma. , 1955, Lancet.